EMulate Therapeutics Inc. Announces Publication of Clinical Results at the SNO 2023 Conference: GBM and DIPG
BELLEVUE, Wash.--(BUSINESS WIRE)--Emulate, Inc. (EMTx) proudly announced today the acceptance of their abstract for presentation and publication in the 28th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 2023, in Vancouver, British Columbia. The accepted abstract will be published in SNO’s official journal, Neuro-Oncology, which is now available at https://academic.oup.com/neuro-oncology/supplements.
The abstract describes the poster material developed by EMTx for the SNO meeting and can be downloaded from EMTx’s website for viewing here. The title of the abstract and poster are: “Low/Ultra-low Radio Frequency Magnetic Field Therapies for the Treatment of CNS Tumors: rGBM and DIPG – Past and Current Results Using the EMulate Therapeutics, Inc. Technology.”
“EMTx continues to move forward with research in support of the humanitarian device exemption (HDE) application to FDA,” said Chris Rivera, CEO of EMTx. “The data we are presenting in our SNO poster demonstrates mechanisms of action and increased survival time in a DMG/DIPG animal model of the EMTx technology using the A1A signal. These data are in addition to safety and benefit data demonstrated in our compassionate use study for the DMG/DIPG indication.”
“We believe that the results and publication of our recurrent glioblastoma clinical trials may provide support in our HDE application for DMG/DIPG,” stated Dr. Xavier Figueroa, Pre-clinical Director for EMTx. “While there is no guarantee that our HDE application will be approved, the needs of this underserved pediatric population and the demonstrated safety profile of our therapeutic device give us reason to feel confident that the FDA will grant us HDE approval.”
Diffuse intrinsic pontine glioma (DIPG, a subset of diffuse midline glioma) primarily affects children, mostly diagnosed between 5 and 7 years of age. DIPG makes up 10-15% of all brain tumors in children, with about 150-300 new diagnoses per year in the United States. Unfortunately, median survival for children diagnosed with this disease is only 9-10 months.
Glioblastoma multiforme (GBM) is the most common type of malignant (cancerous) brain tumor in adults. More than 13,000 Americans are diagnosed with GBM every year. GBM accounts for almost half of all cancerous brain tumors. GBM commonly affects people aged 45 to 70. Most people live on average 12 to 18 months after diagnosis. Only about 7% of people are still alive in five years.
EMTx is dedicated to changing the treatment and prolonging survival in both DIPG and GBM.
About EMulate Therapeutics, Inc.
EMulate Therapeutics is a clinical stage company, reshaping the therapeutic treatment landscape with digital medicines using its proprietary radio frequency energy technology (RFE) targeted at the low and ultra-low ends of the RFE spectrum (ulRFE®) to emulate the effects of drugs and other therapies in treating patients, without the administration of physical drug substances themselves. The use of ulRFE has been shown to be safe to date and the potential therapeutic benefits, specifically targeted at patients’ underlying conditions, continue to be evaluated in multiple studies. This versatile, non-invasive platform technology may provide a solution for patients with cancer, acute and chronic pain, mental health disorders and other serious conditions. The company has generated encouraging human data from patients afflicted with glioblastoma and diffuse midline glioma and is preparing for pivotal (phase III) studies in each indication. It has also generated encouraging preclinical studies in pain management and mental health models and is preparing for initial human clinical trials in each area. In addition, positive data have been generated independently in animal health (positive cancer results in over 20 different solid tumor types in canines (pets)), as well as in bio-agriculture models. EMulate Therapeutics is the licensor of its proprietary technology to Hapbee Technologies, Inc. (HAPB: TSVX). Hapbee is a commercial stage consumer wellness-wearable technology company spun out from EMulate in 2019. EMulate is the largest independent shareholder in Hapbee and recipient of quarterly royalties from net sales.
About EMTx’s ulRFE Device
EMulate Therapeutics (EMTx) has developed a non-sterile, non-invasive, non-thermal, non-ionizing, battery-powered, portable investigational medical device that uses low to ultra-low level (DC-22kHz) frequencies to deliver specific electromagnetic fields to produce specific biological effects, including, e.g., increasing tubulin polymerization in numerous cancer models, emulating the effects of psychedelic drugs in mental health models and reducing pain sensations, among others. The system emits a low power magnetic field (< 100 mG) that can be applied locally or globally, dependent on the type of therapeutic effect sought. The EMTX signals are stored as WAV files on the device and emitted via a cable to the attached antenna unit.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release contains “forward-looking statements.” Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements may include words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “could,” “should,” “would,” “plan,” “project,” “forecast,” and “potential,” the negatives thereof or similar expressions. Forward-looking statements speak only as of the date made, are based on various underlying assumptions and current expectations about the future and are not guarantees of future performance. While we believe these assumptions and expectations are reasonable, are made in good faith and have a reasonable basis, assumed facts or bases almost always vary from actual results, and the differences between assumed facts or expectations and actual results can be material, depending on the circumstances. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievement to be materially different from the results of operations or plans expressed or implied by such forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates, or to regard them as representations that the results or conditions described in such statements will occur or that our objectives and plans will be achieved.
Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.
Source: EMulate Therapeutics, Inc.